Eric Francois - 04 Mar 2026 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Reporting relationship: Director
Issuer ticker: CERO
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Apr 2026, 19:46:43 UTC
Prior SEC filing: 21 Apr 2026
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Kucharchuk, Attorney-in-Fact

Key filing fact

Eric Francois filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 21 Apr 2026.

Key facts

This page summarizes Eric Francois's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Apr 2026, 19:46.

Change

Previous filing in this sequence was filed on 21 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001656125 Primary reporting owner

Francois Eric

Relationship: Director
Address: CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO
Signature: /s/ Andrew Kucharchuk, Attorney-in-Fact
Signature date: 21 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,823,278
Change %
Price: $0.000000^*
Shares after: 1,823,278
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,823,278
Exercise price: $0.0550
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date.